RAD 101 Phase 2b trial demonstrated 93% concordance with MRI across all evaluable lesions, meeting the Phase 2 trial's primary endpoint ...
Ocular Therapeutix's AXPAXLI is the closest investigational competitor. Ocular Therapeutix recently announced positive Phase ...
Toxicity monitoring in phase I/II clinical trials with applications at James Graham Brown Cancer Center Clinical Trials. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This ...
This second project continued the partnership between the Colorado Department of Public Health and Environment (CDPHE) and the Community Engagement, Design and Research (CEDaR) Center to translate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results